Physician profile
Vincent Vincent
NPI 1356323497
$354.13
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $57.03.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $71.49 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.66 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.83 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $36.66 | 2019-2020 | |
| Celgene Corporation | $32.46 | 2019 | |
| Amgen INC. | $26.57 | 2019 | |
| Akorn, INC. | $23.62 | 2020 | |
| Eusa Pharma (US) LLC | $16.29 | 2019 | |
| Partner Therapeutics, INC. | $16.28 | 2019 | |
| Eisai INC. | $14.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.23 | 2019 | |
| Clovis Oncology, INC. | $12.62 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.